Corvus Pharmaceuticals, Inc. (CRVS) shareholders
Close on Nov 17, 2026Market cap $855.51MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Orbimed Advisors LLC Joint filing with Orbimed Capital Gp V LLC (12.20%) | 9,785,423 | 12.20% | 13D (active) amendment | May 12, 2025 |
| Orbimed Capital Gp V LLC Joint filing with Orbimed Advisors LLC (10.30%) | 8,609,091 | 10.30% | 13D (active) amendment | Jan 23, 2026 |
| Sirenia Capital Management LP Joint filing with Alex Silverstein (7.50%) | 6,831,828 | 7.50% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 6,325,157 | 7.50% | 13G (passive) amendment | Jun 30, 2026 |
| Richard A. Miller | 6,085,922 | 7.80% | 13G (passive) amendment | Dec 31, 2025 |
| Samlyn, LP Joint filing with Samlyn Capital, LLC (6.00%), Robert Pohly (6.00%) | 4,065,935 | 6.00% | 13G (passive) amendment | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRVS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Orbimed Advisors LLC | 7,165,006 | 8.52% | $107.05M | – | 1.98% |
| BlackRock, Inc. | 7,138,811 | 8.49% | $106.65M | +978,389 | 0.00% |
| State Street Corp | 4,474,091 | 5.32% | $66.84M | +908,099 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 3,789,126 | 4.50% | $56.61M | +871,826 | 0.01% |
| Vanguard Capital Management LLC | 3,292,710 | 3.91% | $49.19M | +58,172 | 0.00% |
| Adams Street Partners LLC | 3,275,616 | 3.89% | $48.94M | – | 11.06% |
| Vivo Capital, LLC | 2,805,816 | 3.34% | $41.92M | – | 3.83% |
| Wellington Management Group Llp | 2,731,632 | 3.25% | $40.81M | +413,115 | 0.01% |
| Perceptive Advisors LLC | 2,667,441 | 3.17% | $39.85M | +375,000 | 0.60% |
| Deep Track Capital, LP | 2,491,939 | 2.96% | $37.23M | +400 | 0.54% |
| Braidwell LP | 2,126,298 | 2.53% | $31.77M | +373,500 | 1.18% |
| Geode Capital Management, LLC | 1,853,659 | 2.20% | $27.70M | +140,918 | 0.00% |
| Foresite Capital Management VI LLC | 1,831,233 | 2.18% | $27.36M | – | 4.26% |
| Goldman Sachs Group Inc | 1,576,352 | 1.87% | $23.55M | +35,543 | 0.00% |
| Hood River Capital Management LLC | 1,571,805 | 1.87% | $23.48M | +236,696 | 0.17% |
| Morgan Stanley | 1,344,736 | 1.60% | $20.09M | −1,154,089 | 0.00% |
| Boxer Capital Management, LLC | 1,100,000 | 1.31% | $16.43M | – | 1.24% |
| Catalio Capital Management, LP | 1,080,888 | 1.28% | $16.15M | +188,955 | 3.03% |
| Millennium Management LLC | 1,047,985 | 1.25% | $15.66M | +181,623 | 0.01% |
| Vanguard Portfolio Management LLC | 814,750 | 0.97% | $12.17M | +144,855 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 174 | 71M | 84.1% | 41 / 70 | 40 / 30 | 10M | 9M |
| Q1 2026 | 164 | 70M | 83.3% | 68 / 55 | 30 / 26 | 35M | 8M |
| Q4 2025 | 124 | 47M | 55.6% | 30 / 42 | 28 / 7 | 13M | 8M |
| Q3 2025 | 102 | 42M | 49.6% | 23 / 34 | 17 / 13 | 3M | 3M |
| Q2 2025 | 92 | 42M | 49.8% | 33 / 32 | 10 / 29 | 14M | 9M |
| Q1 2025 | 88 | 36M | 43.1% | 16 / 26 | 23 / 13 | 4M | 5M |
| Q4 2024 | 85 | 38M | 44.9% | 32 / 30 | 12 / 8 | 12M | 4M |
| Q3 2024 | 62 | 30M | 35.8% | 19 / 17 | 9 / 3 | 6M | 3M |
| Q2 2024 | 47 | 28M | 32.8% | 7 / 11 | 11 / 7 | 10M | 1M |
| Q1 2024 | 47 | 19M | 22.0% | 7 / 11 | 13 / 8 | 1M | 2M |
| Q4 2023 | 48 | 19M | 23.1% | 3 / 13 | 11 / 7 | 1M | 1M |
| Q3 2023 | 52 | 19M | 22.8% | 10 / 15 | 12 / 10 | 1M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
167 funds held CRVS in Q2 2026, 59% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CRVS | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,931,644 | 3.49% | $43.80M | 0.41% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 2,374,106 | 2.82% | $35.47M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 1,748,043 | 2.08% | $26.12M | 0.03% | Jun 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 963,958 | 1.15% | $14.40M | 0.10% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 844,722 | 1.00% | $12.62M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 801,900 | 0.95% | $11.98M | 0.12% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 740,514 | 0.88% | $9.82M | 0.03% | Jul 31, 2026 |
| Hood River Small-Cap Growth Fund | 707,193 | 0.84% | $10.57M | 0.16% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 625,770 | 0.74% | $9.35M | 0.06% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 616,391 | 0.73% | $9.21M | 0.08% | Jun 30, 2026 |
| iShares Biotechnology ETF | 445,673 | 0.53% | $6.66M | 0.07% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 380,913 | 0.45% | $4.73M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 330,863 | 0.39% | $4.11M | 0.02% | May 31, 2026 |
| Vanguard Explorer Fund | 290,675 | 0.35% | $3.85M | 0.02% | Jul 31, 2026 |
| iShares Micro-Cap ETF | 223,599 | 0.27% | $3.34M | 0.22% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Richard A. Miller Md | President and CEO, Director | 2,331,742 | 2.77% | May 20, 2026 |
| Jeffrey Arcara | Chief Business Officer | 4,500 | 0.01% | Nov 13, 2026 |
| Leiv Lea | Chief Financial Officer | 282,444 | 0.34% | Dec 8, 2025 |
| William Benton Jones | See Remarks | 173,130 | 0.21% | Dec 8, 2025 |
| den Broek Richard van | Director | 160,000 | 0.19% | Jun 15, 2026 |
| David Scott Moore | Director | 21,700 | 0.03% | Jun 15, 2026 |
| Linda Grais | Director | 10,000 | 0.01% | Jun 15, 2026 |
| Peter A. Thompson | Director, 10% owner | 8,729,091 | 10.38% | Jun 15, 2026 |
| Ian T. Clark | Director | – | – | Jun 15, 2026 |
| Andrew C. Chan | Director | – | – | Apr 27, 2026 |
| Capital GP V. LLC OrbiMed | Director, 10% owner | 6,943,654 | 8.25% | Jul 1, 2025 |
| Advisors Llc Orbimed | Director, 10% owner | 8,341,338 | 9.92% | Jul 1, 2025 |
| Scott W. Morrison | Director | – | – | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Jeffrey Arcara Chief Business Officer | Nov 13, 2026 | Buy | +500 | $10.71 | $5.35K | 4,500 |
| Jeffrey Arcara Chief Business Officer | Nov 13, 2026 | Buy | +503 | $10.37 | $5.22K | 4,000 |
| Jeffrey Arcara Chief Business Officer | Nov 12, 2026 | Buy | +497 | $11.12 | $5.52K | 3,497 |
| Jeffrey Arcara Chief Business Officer | Nov 11, 2026 | Buy | +3,000 | $11.46 | $34.38K | 3,000 |
| David Scott Moore Director | Jun 11, 2026 | Buy | +21,700 | $11.53 | $250.20K | 21,700 |
| Richard A. Miller Md President and CEO, Director | May 18, 2026 | Buy | +1,932 | $12.01 | $23.20K | 1,195,035 |
| Richard A. Miller Md President and CEO, Director | May 18, 2026 | Buy | +5,000 | $12.05 | $60.25K | 1,193,103 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $2.74 | $41.10K | 120,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $1.64 | $24.60K | 195,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $2.49 | $37.35K | 180,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $0.97 | $14.55K | 165,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $0.99 | $14.85K | 150,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $2.60 | $39.00K | 135,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $2.12 | $31.80K | 210,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $3.27 | $49.05K | 105,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $2.00 | $30.00K | 90,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $3.61 | $54.15K | 75,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $12.50 | $187.50K | 60,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +15,000 | $9.70 | $145.50K | 45,000 |
| Peter A. Thompson Director, 10% owner | Jan 28, 2026 | Option exercise | +30,000 | $15.00 | $450.00K | 30,000 |
| Advisors Llc Orbimed Director, 10% owner | Jun 27, 2025 | Option exercise | +1,397,684 | $3.50 | $4.89M | 8,341,338 |
| Advisors Llc Orbimed Director, 10% owner | Jun 27, 2025 | Sale | −1,176,332 | $4.16 | $4.89M | 7,165,006 |
| Peter A. Thompson Director, 10% owner | Jun 27, 2025 | Sale | −1,176,332 | $4.16 | $4.89M | 7,165,006 |
| Peter A. Thompson Director, 10% owner | Jun 27, 2025 | Option exercise | +1,397,684 | $3.50 | $4.89M | 8,341,338 |
| William Benton Jones See Remarks | Jun 4, 2025 | Option exercise | +19,357 | $3.50 | $67.75K | 173,130 |
| Richard A. Miller Md President and CEO, Director | May 7, 2025 | Option exercise | +559,073 | $3.50 | $1.96M | 1,136,707 |
| Richard A. Miller Md President and CEO, Director | May 10, 2024 | Gift | −302,016 | – | – | 1,188,103 |
| William Benton Jones See Remarks | May 6, 2024 | Buy | +20,000 | $1.73 | $34.60K | 153,773 |
| Richard A. Miller Md President and CEO, Director | May 6, 2024 | Buy | +577,634 | $1.73 | $999.31K | 577,634 |
| Linda Grais Director | May 15, 2023 | Buy | +10,000 | $2.45 | $24.50K | 10,000 |
| William Benton Jones See Remarks | Dec 20, 2022 | Buy | +20,000 | $0.79 | $15.80K | 133,773 |
| Richard A. Miller Md President and CEO, Director | Dec 14, 2022 | Buy | +10,000 | $0.78 | $7.80K | 1,490,119 |
| Leiv Lea Chief Financial Officer | Dec 14, 2022 | Buy | +4,000 | $0.84 | $3.36K | 133,238 |
| Richard A. Miller Md President and CEO, Director | Dec 13, 2022 | Buy | +50,000 | $0.74 | $37.00K | 1,480,119 |
| Leiv Lea Chief Financial Officer | Dec 13, 2022 | Buy | +30,000 | $0.74 | $22.20K | 129,238 |
| Richard A. Miller Md President and CEO, Director | Sep 28, 2022 | Buy | +25,000 | $0.76 | $19.00K | 1,394,405 |
| Richard A. Miller Md President and CEO, Director | Sep 20, 2022 | Buy | +12,300 | $0.81 | $9.96K | 1,361,705 |
| Richard A. Miller Md President and CEO, Director | Sep 20, 2022 | Buy | +5,000 | $0.82 | $4.10K | 1,369,405 |
| Richard A. Miller Md President and CEO, Director | Sep 20, 2022 | Buy | +2,700 | $0.82 | $2.21K | 1,364,405 |
| Richard A. Miller Md President and CEO, Director | Jun 27, 2022 | Buy | +5,000 | $1.00 | $5.00K | 1,349,405 |
| Richard A. Miller Md President and CEO, Director | Jun 24, 2022 | Buy | +5,000 | $1.03 | $5.15K | 1,344,405 |
| Richard A. Miller Md President and CEO, Director | Jun 6, 2022 | Buy | +890 | $1.01 | $899 | 1,339,405 |
| Richard A. Miller Md President and CEO, Director | Jun 2, 2022 | Buy | +170 | $0.97 | $165 | 1,338,515 |
| Richard A. Miller Md President and CEO, Director | Jun 2, 2022 | Buy | +4,830 | $0.98 | $4.73K | 1,338,345 |
| Richard A. Miller Md President and CEO, Director | Mar 31, 2022 | Buy | +15,000 | $1.64 | $24.60K | 1,333,515 |
| Richard A. Miller Md President and CEO, Director | Mar 17, 2022 | Buy | +5,000 | $1.59 | $7.95K | 1,318,515 |
| Leiv Lea Chief Financial Officer | Mar 17, 2022 | Buy | +13,878 | $1.65 | $22.90K | 99,238 |
| Leiv Lea Chief Financial Officer | Mar 16, 2022 | Buy | +35,160 | $1.54 | $54.15K | 85,360 |
| Richard A. Miller Md President and CEO, Director | Mar 15, 2022 | Buy | +25,000 | $1.47 | $36.75K | 1,313,515 |
| EcoR1 Capital, LLC 10% owner | Oct 1, 2021 | Sale | −2,000,000 | $4.96 | $9.92M | 81,077 |
| EcoR1 Capital, LLC 10% owner | Sep 30, 2021 | Sale | −3,000,000 | $5.04 | $15.12M | 2,081,077 |
| Peter A. Thompson Director, 10% owner | Sep 20, 2021 | Sale | −1,109,644 | $6.09 | $6.76M | 6,943,654 |
| Capital GP V. LLC OrbiMed Director, 10% owner | Sep 20, 2021 | Sale | −1,109,644 | $6.09 | $6.76M | 6,943,654 |
| Richard A. Miller Md President and CEO, Director | Aug 20, 2021 | Buy | +10,000 | $1.93 | $19.30K | 1,288,515 |
| Richard A. Miller Md President and CEO, Director | May 4, 2021 | Buy | +35,714 | $2.80 | $100.00K | 35,714 |
| Peter A. Thompson Director, 10% owner | Feb 17, 2021 | Buy | +1,285,714 | $3.50 | $4.50M | 8,053,298 |
| Advisors Llc Orbimed Director, 10% owner | Feb 17, 2021 | Buy | +1,285,714 | $3.50 | $4.50M | 8,053,298 |
| Richard A. Miller Md President and CEO, Director | Feb 17, 2021 | Buy | +100,000 | $3.50 | $350.00K | 1,278,515 |
| Holdings A/S Novo 10% owner | Jul 8, 2020 | Sale | −741,440 | $5.37 | $3.98M | 1,389,498 |
| Holdings A/S Novo 10% owner | Jul 7, 2020 | Sale | −796,622 | $5.25 | $4.18M | 2,130,938 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Corvus Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 42,687 shares on Sep 21, 2026 over the last 90 days.
See a number that looks wrong?